|
|
 |
|
Viewing report
|
|
|
|
Monoclonal Antibodies: 2010
Datamonitor, Oct 2010, Pages: 201
Introduction
Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company
Features and benefits
- Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.
- The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.
- The impact of biosimilars on future MAb sales growth is evaluated and compared with small molecule brand sales following genericization
Highlights
While it is believed that biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.
Your key questions answered
- Assess the outlook for the monoclonal antibodies sector through to 2015
- Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe
- Appraise the technological developments being made in the sector and see where monoclonal antibody pipelines are being focussed
|
|
|
|
